Royalty Pharma (RPRX) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for June 4, 2026, in New York, with voting available online or in person.

• Shareholders are encouraged to review proxy materials and annual reports before voting.

Voting matters and shareholder proposals

• Election of nine directors, with all nominees recommended for approval.

• Advisory vote on executive compensation and approval of the U.K. directors' remuneration report.

• Ratification of Ernst & Young LLP as independent registered public accounting firm and re-appointment as U.K. statutory auditor.

• Approval of U.K. audited annual report and accounts for the fiscal year ended December 31, 2025.

• Authorization for the Board to allot shares, determine auditor remuneration, and purchase Class A ordinary shares.

• Special resolution to authorize the Board to allot shares without rights of pre-emption.

Board of directors and corporate governance

• Nine director nominees listed, including individuals with medical, financial, and leadership backgrounds.

• Board recommends voting in favor of all director nominees.